Identity and synonyms
Tyr-hGH(177–191); not hCG and not automatically equivalent to hGH fragment 176–191.
Synonyms: Tyr-hGH(177–191) · AOD9604 · AOD 9064 (source spelling; provisional correction)
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Modified GH fragment
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Proposed metabolic effects of a GH-related fragment; not full-length GH replacement.
Evidence and critical reading
Reported scientific and empirical uses
Reported weight management
Handbooks describe subcutaneous uses and joint combinations with hyaluronic acid. The guide separates obesity, joint repair and each formulation rather than treating them as interchangeable applications.
Human evidence
The obesity development program did not establish clinically useful weight-loss efficacy. Oral/IV safety summaries do not validate community subcutaneous use.
Preclinical evidence
Animal lipolysis findings did not establish human obesity treatment.
Critical reading and limitations
The FDA assessment reviews an obesity program including a trial without significant weight-loss benefit. That result does not validate an alternative injection regimen. A handbook quantity remains attributed to its source; an insufficiently supported safety claim is identified accordingly.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
0.3 mg · Amount per administration
- Frequency
- Once daily
- Duration
- 20 days
- Route
- Subcutaneous
- Context
- Handbook metabolic-use context; no approved indication established here.
- Presentation
- Concentration: 1.2 mg/mL · Container volume: 5 mL
- Interpretation
- Documentary handbook claim, not a validated regimen. Its safety assertion requires independent checking; FDA describes limited safety information and potential risks.
manual01 · Page 22 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US: investigational; advisory assessment is not approval.
Adverse effects and unknowns
Limited route-specific safety and immunogenicity concerns; no basis for claims of no proliferative risk.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
AOD-9604 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- R04
- R06
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026